SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers

• The biotechnology company previously reported cash and cash equivalents of $107.1 million and has since received around $28.7 million in proceeds from the exercise of common stock warrants.
• CEO Stergiou stated that a capitalized runway provides the financial flexibility required to execute the firm’s strategic milestones.
• Investors eye updates from Sellas’ late-stage trial of GPS in acute myeloid leukemia.

Retail-favorite Sellas Life Sciences (SLS) captured Wall Street’s attention on Tuesday after strengthening its cash reserves through recent warrant exercises, with CEO Angelos M. Stergiou highlighting an expanded capital runway that positions the biotech to pursue key clinical milestones and strategic growth opportunities.

SLS shares were down around 2.5% at the time of writing.

SLS Adds $28.7M To Cash Runway

The biotechnology company previously reported cash and cash equivalents of $107.1 million as of March 31, 2026. Since then, Sellas has received around $28.7 million in proceeds from the exercise of common stock warrants in April and May.

Sellas also disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.

“This capitalized runway provides us with the financial flexibility required to execute our strategic milestones, progress our key therapeutic programs, and ultimately work toward delivering life-changing treatments to patients in need,” Stergiou said in a post on LinkedIn on Tuesday.

Regal Trial In Focus

Investors remain focused on Sellas Life Sciences’ late-stage Regal trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML). The study has recorded 78 of the 80 events needed for the final analysis.

Stergiou said the trial has lasted much longer than expected, which could be a positive sign. He noted that the required 80 events had still not been reached nearly 25 months after enrollment was completed, potentially indicating that patients are surviving longer than originally projected.

Investors are also keeping an eye on SLS009, Sellas’ Phase 2 AML drug candidate, with data expected later this year.

Retail Bulls Brush Off Stock Dip

Retail sentiment on Stocktwits changed to ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘high’ message volumes. One user brushed off the share price dip, stating “all that matters” are the results from SLS’ existing trials.

Another user said the company is “building the foundation for a future AML franchise that the market still dramatically underappreciates.”

SLS shares have soared 224% so far this year.

Read also: ODD Stock Crashes Toward Record Lows, Warns Customer Acquisition Issues Will Weigh On 2026 Revenue Q1 Earnings

For updates and corrections, email newsroom[at]stocktwits[dot]com.